U.S. markets open in 1 hour 27 minutes
  • S&P Futures

    4,066.50
    +61.75 (+1.54%)
     
  • Dow Futures

    32,545.00
    +386.00 (+1.20%)
     
  • Nasdaq Futures

    12,481.00
    +236.25 (+1.93%)
     
  • Russell 2000 Futures

    1,816.40
    +34.00 (+1.91%)
     
  • Crude Oil

    115.38
    +1.18 (+1.03%)
     
  • Gold

    1,833.90
    +19.90 (+1.10%)
     
  • Silver

    21.87
    +0.32 (+1.48%)
     
  • EUR/USD

    1.0541
    +0.0102 (+0.98%)
     
  • 10-Yr Bond

    2.8770
    0.0000 (0.00%)
     
  • Vix

    26.61
    -2.26 (-7.83%)
     
  • GBP/USD

    1.2483
    +0.0159 (+1.29%)
     
  • USD/JPY

    129.3150
    +0.2620 (+0.20%)
     
  • BTC-USD

    30,314.23
    +371.69 (+1.24%)
     
  • CMC Crypto 200

    681.72
    +439.04 (+180.91%)
     
  • FTSE 100

    7,524.57
    +59.77 (+0.80%)
     
  • Nikkei 225

    26,659.75
    +112.70 (+0.42%)
     

FENC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 2, 2020 in the Class Action Filed on Behalf of Fennec Pharmaceuticals Inc. Limited Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - November 2, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) alleging that the Company violated federal securities laws.

Class Period: February 11, 2020 and August 10, 2020
Lead Plaintiff Deadline: November 2, 2020

Learn more about your recoverable losses in FENC:
http://www.kleinstocklaw.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?id=10645&from=5

The filed complaint alleges that Fennec Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facilities for PEDMARK, the Company's sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders have until November 2, 2020 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the FENC lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67355